Table 7.
Interventions influencing QoL in patients with acromegaly (intervention studies).
| Reference | Factor | Study characteristics | Therapy effect (i.e., QoL change after therapy) |
|---|---|---|---|
| Biermasz et al. (22) | Octreotide LAR interval injections | Patients uncontrolled on octreotide LAR (n = 14) receive 8 weeks washout followed by 6-week interval injections during 36 weeks | 0 |
| Bronstein et al. (26) | Crossover pasireotide LAR vs. octreotide LAR | Patients without biochemical control after 1 year of somatostatin analogs switched from either pasireotide LAR or octreotide LAR (follow-up 12 months after crossover) | 0 |
| Caron et al. (28) | Lanreotide autogel | Treatment-naïve patients (n = 90) with macroadenomas received lanreotide autogel during every 28 days for 48 weeks | ++ |
| Caron et al. (29) | Lanreotide autogel | Treatment-naïve patients (n = 90) with macroadenomas received lanreotide autogel during every 28 days for 48 weeks | ++ |
| Chin et al. (32) | Octreotide-LAR | Newly diagnosed patients (n = 58) were prescribed octreotide-LAR for 24 weeks | + |
| Fujio et al. (35) | Pituitary surgery | Newly diagnosed patients (n = 41) who achieved biochemical control after surgery were included | + |
| Ghigo et al. (37) | Pegvisomant vs. octreotide LAR | Medical-treatment and radiotherapy-naïve patients (n = 113), randomization between 4 weeks pegvisomant or octreotide LAR, followed by 48 weeks octreotide | 0 |
| Hatipoglu et al. (38) | Physical activity | Mixed cohort of patients (n = 20) exercised 3 days a week for 3 months. NB response rate <10% | 0 |
| Karaca et al. (40) | Octreotide-LAR | Treatment-näive patients (n = 22) were randomized to either octreotide LAR or pituitary surgery (follow-up 12 months) | 0 |
| Pituitary surgery | 0 | ||
| Lombardi et al. (44) | Lanreotide autogel | Uncontrolled patients (n = 51) received autogel injections every 6–8 weeks (dose titration) for 48–52 weeks | ++ |
| Madsen et al. (45) | Somatostatin analogs vs. somatostatin analogs + pegvisomant | Patients controlled on somatostatin analogs (n = 18) randomized to unchanged continuation of somatostatin analogs or cotreatment with pegvisomant during 24 weeks | 0 |
| Mangupli et al. (46) | Octreotide-LAR | Retrospective observational study, patients (n = 28) on octreotide-LAR were followed for 4 years | ++ |
| Milian et al. (48) | Pituitary surgery | Patients selected for operative treatment (n = 93) were tested preoperatively and 3–12 months after surgery. No information on additional medical treatment | ++ |
| Neggers et al. (50) | Pegvisomant | Placebo-controlled crossover study (n = 20): patients controlled on somatostatin analogs receive addition of pegvisomant during long-acting SA-treatment in controlled patients during 36 weeks (2 × 16 weeks, 4 weeks washout) | ++ |
| GH/change in IGF1 after pegvisomant addition | 0 | ||
| Trainer et al. (61) | Pegvisomant | Patients uncontrolled on octreotide-LAR (n = 27) randomized to pegvisomant monotherapy or addition of pegvisomant to octreotide-LAR | ++ |
| Pegvisomant + long-acting octreotide | ++ | ||
++positive correlation with QoL, +positive correlation with a subscale of QoL only, −− negative correlation with QoL, −negative correlation with a subscale of QoL only, 0 no significant correlation with QoL.